Is this Biotech Play the Next Big Thing?
Innovation, cutting-edge drug technology, clinical expertise, access to capital … all pointing to repeated FDA approvals, accelerated revenue growth and a winning addition to your portfolio.
It’s that time again…
The time where you have the rare opportunity significantly grow the value of your portfolio by an investment in our newly Featured Company. Our BioTech Insiders Team, through ongoing research and due diligence, have identified our next Featured Company in a sector that continues to be on absolute fire and is lining for a big run in 2018.
As you know by now, The Money Street has become known for bringing winning ideas to our Followers (after careful research and consideration) for true additions to your portfolio.
Our Mission continues to be grounded on bringing investment opportunities to people just like you — everyday investors, so you are earning what you deserve to earn on the companies you invest in.
We publish suggestions on our carefully vetted Featured Companies only when we’re deeply rooted in our findings: that your investment has the potential to see substantial gains in the short and long-term. The potential for 30%, 40%, even 100% gains have been seen with our Featured Companies. See for yourself this jewel of a company we’ve just discovered! All our research arrows are pointing to Q BioMed Inc. (OTC: QBIO $0.00 – website) – as being a genuine game changer in the race to deliver more effective treatments for glaucoma, metastatic bone cancer, liver cancer, and rare pediatric autism spectrum disorder.
Q BioMed is self-described as a biotechnology development company focused on the acceleration and commercialization of biotechnology products. We at The Money Street describe them, as a winner in the making.
Its mission is focused on 3 core objectives:
License and acquire pre-commercial innovative life sciences assets in different stages of development and therapeutic areas from academia or small private companies;
License and acquire FDA approved drugs and medical devices with limited current and commercial activity; and
Accelerate and advance its assets to the next value inflection point by providing: strategic capital, business development and financial advice and experienced sector specific advisors
The Company has a core portfolio of four therapeutic products that include:
Its business model is to focus on maximizing risk-adjusted returns by focusing on multiple assets throughout the discovery and development cycle. How it intends to do this is by establishing early positioning in illiquid and/or less well known privately-held assets, and then unlocking value and capitalizing on valuation growth as these assets move forward in their development and toward commercialization.
Our in-depth look into this exciting company starts right now by introducing you to their Chairman & CEO, Denis Corin as he shares his thoughts on the Company’s business model and its opportunities over the next 12 to 18 months.
Mr. Corin speaks about Q BioMed’s accelerated R&D business model and outlook over the next 12 to 18 months:
Mr. Corin shares opinion the exciting developments of one of Q BioMed’s products in its portfolio, QBM-001, which is for rare pediatric non-verbal autism. Mr. Corin believes that the Company is on a brink of a breakthrough that would represent a multi-billion dollar market opportunity for Q BioMed:
Massive Gains Have Historically Been Found In the Biotech Arena
Before we present our specific research findings on Q BioMed Inc. (OTC: QBIO), we think it best to review a bit of the market as well as the leaders that have emerged in the Biotech sector and how they have delivered massive gains to their early investors.
Let’s next look at some incredible winners from the highflying Biotech sector whom we track regularly to continue to source ideas and trends from:
The Winners: Too Late To Invest In, But Good To Study
Market Cap: $3.719B
GW is developing a portfolio of cannabinoid medicines, including Sativex, for the treatment of MS spasticity and cancer pain, and Epidiolex for the treatment of childhood epilepsy. GW’s lead product, Sativex is now approved in 27 countries.
FDA Accepted GW Pharma’s NDA Filing for Epidiolex(R) in the Treatment of Lennox-Gastaut Syndrome and Dravet Syndrome.
Market Cap: $96.533B
This research-based biopharmaceutical company discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead’s portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. The company’s portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
Gilead: The Follower Becomes the Leader.
Market Cap: $2.999B
This biopharmaceutical company is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. The business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure.
Ligand Earns $6 Million as OmniAb Partner Out-Licenses Antibody Projects
Market Cap: $158.653B
What originated in 2013 as a spin-off of Abbott Laboratories already has revenue of $22.86 billion USD (2015). This pharmaceutical company discovers, develops, and markets both biopharmaceuticals and small molecule drugs.
AbbVie’s Upadacitinib Shows Positive Results as Monotherapy in Phase 3 Rheumatoid Arthritis Study, Meeting All Primary and Key Secondary Endpoints
Market Cap: $2.179B
The only blood plasma-based biopharmaceutical company approved by the government of Shandong Province, China Biologic Products Inc. is engaged in research, manufacturing, and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. The company, which made Forbes’ “Asia’s 200 Best Under A Billion” list has $243 million in sales and three-year average sales growth of 16%.
China Biologic Announces Completion of Acquisition of TianXinFu from PWM
Market Cap: $2.53B
Founded 2005, Horizon Pharma Public Limited Company, is a biopharmaceutical company that engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally.
Horizon Pharma Gets FDA Nod for Procysbi Label Expansion
Entry Point Timing Is Everything
Companies like Q BioMed Inc. (OTC: QBIO) are on the cutting edge of asset discovery, giving them the true potential to reach Market Capitalization sizes as noted in the previous sector winners. Recent innovations have lead to revolutionary drugs like Strontium-89 Cancer Palliation drug; QBM-001 for rare pediatric non-verbal autism spectrum disorder; Uttroside-B liver cancer; and the MAN 01 Glaucoma drug, which all are in the process of being brought to the global marketplace by Q BioMed — something every early shareholder dreams of, getting in on the ground floor of a major drug release.
The time to bring this portfolio addition to you couldn’t be any better than right now. Take a look at the following press we located on QBIO, here.
Let us now in detail explain each of Q BioMed’s 4 core assets within their product portfolio and their stage of development:
Strontium 89 – QBIO’s Cancer Palliation Drug (FDA Approved) for metastatic bone cancer pain, is ready for manufacture and sales. The addition of this revenue asset sets this pipeline apart from the majority of small-cap biotech. This asset alone de-risks the investment in Q BioMed and provides a solid base to grow from.
Cancer is when abnormal cells divide in an uncontrolled way. There are more than 200 different types of cancer and by 2025, 19.3 million cancer cases are expected to be diagnosed each year. As of 2012 (the latest year for which information is available), 14.1 million new cases were diagnosed worldwide and 8.2 million people died from cancer. Thanks to research, many people are cured—some 32.6 million people were five-year cancer survivors in 2012.
QBIO has entered into a definitive agreement to exclusively license the FDA Approved drug from a private U.S. company focused on the development of generic pharmaceuticals, which is big business worldwide. The market potential for Bone Cancer Pain Palliation is currently estimated at $300 Million.
From an operations standpoint, Q BioMed has pending regulatory approval on its Sr89 manufacturing facility. The Company is expecting to receive a decision in the next few months. Once approved, this will provide the Company with additional manufacturing competencies to allow it to further execute on its go-to-market plan for the drug.
QBM-001 – QBIO’s drug for rare pediatric non-verbal autism. The Company believes that it is on the right path to pursuing FDA approval for this product as the active molecule in QBM-001 is already well know to the regulators in the use of other drugs. This would allow the opportunity for the QBM-001 to be “accelerated” thru the clinical process and be fast tracked for approval.
The patient market for QBM-001 is a niche market. However, due to the severity of the autism and its lifetime liability to healthcare costs, the economic value for QBM-001 represents a multi-billion dollar market opportunity.
Additionally, it is likely that Q BioMed will pursue Orphan Drug designation for QBM-001. An Orphan Drug designation under the Orphan Drug Act of 1983 affords companies with accelerated regulatory reviews, tax reductions and exclusive rights to developing cures of rare diseases. Exclusivity enhances the economic value of the drug, and would potentially DOUBLE TO TRIPLE Q BioMed’s revenue forecast of QBM-001.
Uttroside-B is currently in development stage and is QBIO’s drug for targeting liver cancer.
According to Market Data Forecast report, the liver cancer market was estimated to be worth $572 Million in 2016 and is tracking at a 9.1% CAGR, which estimates the market to be close a $1 Billion dollar market by 2021.
Liver cancer continues to have an impact as 1 out of every 5 people who are diagnosed with cancer have liver cancer. Additionally, it one of the most potent killers as 1 out of 3 cancer-related deaths are from liver cancer.
Based on these metrics, the Liver Cancer Therapeutics Market is expected to continue to grow in activity, both in new product discoveries as well as competitive positioning for market dominance.
Man 01 – QBIO’s Glaucoma Drug is being brought to market to treat Intraocular Eye Pressure (IOP), with early tests indicating excellent results in normalizing IOP. This drug may be effective in helping ease the symptoms associated with:
Age Related Macular Degeneration (AMD)
Cystic Kidney Disease
Glaucoma accounts for over 10 million visits to physicians each year. In terms of Social Security benefits, lost income tax revenues, and health care expenditures, the cost to the U.S. government is estimated to be over $1.5 billion annually. Glaucoma patients number more than 60 million worldwide, and the Glaucoma market is currently estimated to be between $4.5 to $5 billion in the U.S., EU, and Japan alone.
Q BioMed Inc. (OTC: QBIO) is taking the glaucoma market by storm, by securing the pole position over the industry’s major players. As you will soon see, this innovative company has the jump on the competition with its focus on the ‘Schlemms’ Canal, which is responsible for 70%-90% of fluid drainage in the eye.
From a comp perspective, Aerie Pharmaceuticals has a drug that it is bringing to market to treat glaucoma and has seen its market cap grow from $100 Million to close to $2 Billion. However, the drug is not addressing the massive Schlemms Canal opportunity. This is significant as Q BioMed’s Man 01 Glaucoma drug is THE ONLY DRUG to target the ‘Schlemms’ Canal, which will be a BREAKTHROUGH for the industry. Thus, we believe that Q BioMed stands to garner even more favorable attention than Aerie as a result of this.
QBIO Commands Our Strongest Buy Rating
Through Q BioMed, Inc. investors have the opportunity to invest in some of the most innovative bio-medical products that they may never have known about. Technologies are vetted by analysts, industry KOLs, and experts. Your investment is in Q BioMed Inc. (OTC: QBIO) so you have public company liquidity without being tied up in a private company with an unknown exit strategy and uncertain value inflection milestones (FDA Approval, etc).
Q BioMed mitigates risk by having multiple relationships and assets across a broad spectrum of healthcare companies and sectors. Company success is shared as multiple assets mature at different times in their development cycle, passing on the value to Q BioMed shareholders.
“… QBioMed will have multiple assets at work in multiple areas, some in diagnostics, some in medical devices, some in drugs and ALL having profitable outcomes. Your investments are driven by having multiple short-term events within our portfolio of products – allowing for stable and ongoing calculated returns for our investors.”
The Biotech Index is up 300% since the financial crisis and 2014 was a record IPO year with continued growth, partnerships, and M & A. The demand for affordable quality drugs is unyielding. The Medical and Biotech market is experiencing an unprecedented bull market and pharmaceutical companies are buying their pipelines from innovators like QBIO.
Q BioMed Inc. (OTC: QBIO), currently just a few dollars per share, could emerge as the big winner in the race to end Glaucoma, with its focus on the ‘Schlemms’ Canal. And when you add in Strontium 89, which is FDA Approved for metastatic bone cancer pain; Uttroside-B for liver cancer; and the potential home run with QBM-001 for rare pediatric non-verbal autism, you have a broad and diverse product pipeline that canvasses multi-billion dollar markets.
Our recommendation is that you secure your early position in (Q BioMed Inc. OTC: QBIO) right now. Life-changing gains are possible, now just think about what billions in annual revenues would mean for a burgeoning biotech company like Q BioMed, which currently with a tiny market cap of $53.92 million … a small investment could easily turn into 3X, 10X, 15X etc. if given enough time and execution by the Company … based on its focused model to accelerate its product pipeline towards the next value inflection point that unlocks each drug’s value.
On September 22, 2015, Q BioMed CEO, Denis Corin had this to say in an interview with The Wall Street Analyzer:
“The most unique thing about Q BioMed is that it’s providing access for investors to innovative technologies that are very mature and later-stage. Our model is very different that what is typically expected from biotech investors. Historically investors focused in the biotech micro-cap public sector have to find a single biotech company or product to invest in. Returns on their investment would require a very a patient outlook while the company’s technologies make their way through the regulatory processes with the FDA, etcetera. This is a fairly arduous process, time consuming and the investors are stuck waiting for developments to happen to help generate the liquidity for their investment. For those who favor privately-held biotech companies, where their investments are essentially locked in until their product has reached the major evaluation inflexion point allowing the company to either go public or be acquired … well simply put from our perspective this is just very long and a risky investment.
The goal here for us at Q BioMed is to have multiple assets in different therapeutic areas that will provide constant inflexion points in each of those areas, providing for continual investor liquidity. We do not want our investors just sitting and waiting for one product to work through phase one, phase two, phase three, investors in Q BioMed will have multiple assets at work in multiple areas, some in diagnostics, some in medical devices, some in drugs and all having profitable outcomes. So, your investments returns are driven by having, multiple short-term events within our portfolio of products. Allowing for stable ongoing calculated returns for our investors.”
We find Mr. Corin’s 2015 interview very prophetic. Under Mr. Corin’s leadership, Q BioMed has grown is product pipeline to 4 products which has demonstrated his ability to execute on his vision. We believe that Q BioMed’s management team has executed very well against its target milestones over the last 2 years, and we look forward to seeing the company continue to achieve its next set of milestones in 2018 and 2019.
Additionally, there have been some significant corporate developments that have recently occurred, possibly showing their hand in the goals for an near-term up-listing to NASDAQ.
Specifically, the company has retired all of its debt; has added independent directors to its Board, and is raising shareholder friendly capital to bolster its balance sheet reserves. These activities are commonly done by companies who are readying themselves to up-list to a major exchange. We believe that Q BioMed’s recent corporate structural activities have positioned the company for a similar opportunity, and it is something that potential investors will want to factor into their decision, sooner rather than later.
We would not be surprised in the least if we see an early share-price double in the coming months as next round news is released on Q BioMed Inc. (OTC: QBIO), but first things first. In order to be in the game you must own QBIO. Don’t you end up kicking yourself later for missing out, so start your own research on Q BioMed, Inc. now and be sure to show this information to your broker. Everything we have noted above is easy to verify through publicly available sources and we are confident that you will agree that Q BioMed holds strong upside from current price levels.
Remember, with every stock situation, it is crucial that you follow our stated mantra of protecting partial gains on your way up. We’ll also be announcing specific profit intervals that you can follow each and every step of the way at TheMoneyStreet .com.
- The Money Street Health Care Trends Team
+ Market Trends
+ Profitable Stock Picks
… and more
SIGN UP TODAY!
Dont Yet Have a Broker?
SUBSCRIBE TO THE BEAT
Now includes EVEN MORE of what you love…
Leading Industry News, Market Trends, Profitable Stock Picks and more. SIGN UP TODAY!